Allovir Inc Multi-Virus Prevention Approach in the Management of Allo-HCT Patients - Corporate Call Transcript
Good afternoon, and welcome to AlloVir's virtual investor event to discuss the opportunity for posoleucel multi-virus prevention. I'm Sonia Choi, AlloVir's Senior Vice President of Corporate Affairs and Investor Relations and your host for today's call. During the call, AlloVir's Chief Executive Officer, Dr. Diana Brainard, will provide a clinical overview, after which Dr. Sanjeet Dadwal, Chief of Infectious Diseases and Professor of Medicine at City of Hope, will walk us through the final data from a Phase II multi-virus prevention study of the investigational virus-specific T cell therapy posoleucel. These data were presented at the American Society of Hematology Annual Meeting over the weekend.
Following Dr. Dadwal's presentation, Dr. Brainard will host a fireside chat with both Dr. Dadwal and Dr. Joseph McGuirk, a hematologist, oncologist and transplant specialist at University of Kansas Medical Center. During the fireside chat, we will discuss the unmet need and prevention approach for posoleucel in allogeneic hematopoietic stem
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
